Profile
GLS NVO VRTX REGN SGEN MRNA
Company Name Gelesis Holdings, Inc. Novo Nordisk A/S Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Seagen Inc. Moderna, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $11.63M $550.22B $102.67B $95.34B $43.15B $41.34B
Employees 0.09K 63.37K 5.40K 13.45K 3.26K 5.60K
CEO Mr. Yishai Zohar Mr. Lars Fruergaard Jorgensen Dr. Reshma Kewalramani FASN, M.D. Dr. Leonard S. Schleifer M.D., Ph.D. Mr. David R. Epstein B.Sc., M.B.A. Mr. Stephane Bancel
Ratings
GLS NVO VRTX REGN SGEN MRNA
Quant Rating Score 3 5 5 5 3 4
Quant Rating Neutral Strong Buy Strong Buy Strong Buy Neutral Buy
Trading
GLS NVO VRTX REGN SGEN MRNA
Last Close $0.1586 $126.85 $397.48 $883.2 $228.74 $107.97
High 52 $0.16 $199.54 $446.08 $993.35 $228.9 $137.75
Low 52 $0.16 $87.78 $323.57 $692.45 $187.64 $69.51
Price vs. 52 Week High -0.88 % -36.43 % -10.89 % -11.09 % -0.07 % -21.62 %
Price vs. 52 Week Low -0.88 % 44.51 % 22.84 % 27.55 % 21.9 % 55.33 %
Total Return
GLS NVO VRTX REGN SGEN MRNA
1 Month Return 0 % -1.21 % -4.91 % -8.24 % 0 % 1.32 %
3 Month Return 0 % 17.38 % -7.6 % -6.05 % 0 % 6.05 %
6 Month Return 0 % 35.67 % 11.88 % 13.93 % 6.59 % 50.15 %
9 Month Return 0 % -19.62 % 12.27 % 18.38 % 19.07 % -9.01 %
YTD Return 0 % 22.62 % -2.31 % 0.56 % 0 % 8.57 %
1 Year Return 0 % -24.08 % 16.66 % 10.15 % 14.37 % -18.75 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
GLS NVO VRTX REGN SGEN MRNA
Dividend Yield Percentage (TTM) - 1.43 % - - - -
Dividend Paid and Capex Coverage Ration (TTM) -11.66 % 1.54 % 13.69 % 5.88 % -3.35 % -4.41 %
Dividend Per Share (TTM) - 1.81 % - - - -
Payout Ratio (TTM) - 37.96 % - - - -
Growth
GLS NVO VRTX REGN SGEN MRNA
Asset Growth -29.38 % 30.35 % 25.23 % 13.23 % -1.21 % -28.74 %
Gross Profit Growth -249 % 32.32 % 9.25 % 6.49 % 22.93 % -85.12 %
Revenue Growth 130.37 % 31.26 % 10.17 % 7.76 % 24.65 % -64.94 %
Revenue 3 Year - 90.51 % 59.87 % 56.27 % 91.84 % 2354.12 %
Revenue 5 Year - 124.2 % 218.58 % 97.36 % 215.48 % 1070.62 %
Revenue 10 Year - 66.11 % 608.27 % 509.63 % 494.04 % 6447.35 %
EBIT Growth -43.35 % 37.11 % -12.94 % -14.6 % 10.13 % -145 %
Net Income Growth 40.24 % 50.71 % 8.96 % -8.87 % 9.51 % -156.37 %
Net Income 3 Yeari Growth Per Share - 106.79 % 34.59 % 13.92 % -764.83 % -529.35 %
Net Income 5 Yeari Growth Per Share - 133.86 % 70.33 % 63.31 % -276.93 % -160.17 %
Net Income 10 Yeari Growth Per Share - 98.61 % 809.6 % 811.34 % -624.16 % -2046.03 %
Operating Income Growth -43.35 % 37.11 % -12.94 % -14.6 % 10.13 % -145 %
Operating Cash Flow Growth (CFG) -40.58 % 38.06 % -14.35 % -8.39 % 9.07 % -162.6 %
Operating 3 Year CFG - 118.29 % 9.63 % 77.63 % -148.34 % -253.42 %
Operating 5 Year CFG - 163.51 % 174.78 % 111.31 % -195.86 % -100.11 %
Operating 10 Year CFG - 150.92 % 5187.08 % 663.48 % -2622.09 % -4698.89 %
EPS Growth 95.17 % 52.28 % 8.33 % -8.54 % 10.81 % -158.04 %
EPS Diluted Growth 95.17 % 52.37 % 8.35 % -9.03 % 10.81 % -161.33 %
Book Value Per Share 99.38 % 29 % 25.58 % 14.4 % -9.83 % -21.18 %
Share Holder 3 Year Equity Growth Per Share - 75.22 % 104.06 % 138.48 % 33.92 % 439.47 %
Share Holder 5 Year Equity Growth Per Share - 121.9 % 291.14 % 199.46 % 220.81 % 92.24 %
Share Holder 10 Year Equity Growth Per Share - 49.62 % 1030.79 % 1201.51 % 691.19 % 1519.81 %
Dividend Per Share Growth - 26.89 % - - - 59.65 %
Dividend 3 Year Growth Per Share - 64.4 % -100 % - - 3725.19 %
Dividend 5 Year Growth Per Share - 80.03 % -100 % - - -
Dividend 10 Year Growth Per Share - 95.44 % - - - -
Debt Growth -6.05 % 4.74 % 44.1 % 0.06 % -23.28 % 3.58 %
Free Cash Flow Growth -15.48 % 9.17 % -16.47 % -17.11 % 3.67 % -183.5 %
Updated On 31 Dec 2022 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2022 31 Dec 2023
Profitability
GLS NVO VRTX REGN SGEN MRNA
Gross Profit Margin TTM -57.3 % 84.6 % 87.21 % 87.87 % 75.4 % 31.49 %
Return on Assets TTM -52.56 % 26.61 % 15.92 % 11.95 % -20.64 % -25.58 %
Return on Equity TTM 272.51 % 90.49 % 22.62 % 16.07 % -28.06 % -29.87 %
Return on Capital Employed TTM -343.14 % 70.82 % 19.82 % 13.65 % -29.5 % -27.51 %
Net Income Per EBT TTM 100.99 % 79.95 % 82.64 % 94.15 % 101.53 % 119.58 %
EBT Per Ebit TTM 75.21 % 102.05 % 115.19 % 103.76 % 93.47 % 92.99 %
EBIT Per Revenue TTM -546.48 % 44.16 % 38.53 % 30.85 % -34.37 % -61.88 %
Cash Flow To Debt Ratio TTM -148.69 % 403.27 % 437.57 % 169.97 % -475.96 % -250.84 %
Receivables Turnover TTM 15.19 3.09 6.31 2.31 3.64 6.34
Payables Turnover TTM - 1.4 3.46 2.62 2.52 9.03
Inventory Turnover TTM 3.36 1.12 1.71 0.62 1.07 23.23
Fixed Asset Turnover TTM 20.88 % 255.34 % 679.28 % 316.35 % 471.71 % 257.71 %
Asset Turnover TTM 12.66 % 73.85 % 43.42 % 39.65 % 63.3 % 37.18 %
Operating Cash Flow Per Share TTM -0.68 24.39 13.73 43.1 -2.87 -8.18
Free Cash Flow Per Share TTM -0.74 15.68 12.72 35.77 -3.73 -10.04
Cash Per Share TTM 10.78 % 677.09 % 4354.48 % 10173.36 % 657.5 % 2258.27 %
Operating Cash Flow Sales Ratio TTM -410.9 % 46.89 % 35.84 % 35.02 % -23.48 % -45.52 %
Free Cash Flow Operating Cash Flow Ratio TTM 108.57 % 64.29 % 92.69 % 83.01 % 129.82 % 122.67 %
Cash Flow Coverage Ratios TTM -148.69 % 403.27 % 437.57 % 169.97 % -475.96 % -250.84 %
Price To Free Cash Flows Ratio TTM -0.21 54.8 31.31 25 -61.54 -10.81
Price To Operating Cash Flows Ratio TTM -0.23 36.26 28.96 20.49 -79.67 -13.19
Price Cash Flow Ratio TTM -0.23 36.26 28.96 20.49 -79.67 -13.19
Income Statement (TTM)
GLS NVO VRTX REGN SGEN MRNA
Revenue $0.03B $232.26B $9.84B $13.12B $1.96B $6.75B
Gross Profit $-0B $196.5B $8.58B $11.3B $1.55B $2.06B
Gross Profit Ratio -6.95% 84.6% 87.17% 86.16% 79.1% 30.52%
EBITDA $-0.11B $112.94B $3.93B $5.13B $-0.62B $-3.21B
Net Income $-0.06B $83.68B $3.62B $3.95B $-0.61B $-4.71B
EPS Diluted -0.79 18.62 13.89 34.77 -3.3 -12.34
Balance Sheet (MRQ)
GLS NVO VRTX REGN SGEN MRNA
Long Term Debt $0.03B $20.53B $0.72B $2.7B $0.04B $1.22B
Total Liabilities $0.1B $207.93B $5.15B $7.11B $0.87B $4.57B
Total Equity $-0.01B $106.56B $17.58B $25.97B $2.8B $13.85B
Total Investments $0B $17.5B $3.45B $13.51B $1.42B $4.68B
Total Debt $0.06B $27.01B $0.81B $2.7B $0.04B $1.24B
Total Assets $0.1B $314.49B $22.73B $33.08B $3.67B $18.43B
Cash Flow Statement (TTM)
GLS NVO VRTX REGN SGEN MRNA
Net Income $-0.06B $83.68B $3.62B $3.95B $-0.61B $-4.71B
Inventory $-0.01B $-7.42B $-0.32B $-0.27B $-0.23B $0.75B
Dividends Paid $0B $-31.77B $0B $0B $0B $0B
Operating Cash Flow $-0.08B $108.91B $3.54B $4.59B $-0.45B $-3.12B
Capital Expenditure $-0.01B $-38.9B $-0.26B $-0.93B $-0.08B $-0.71B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 1.75
ABCL AbCellera Biologics Inc. 3.76
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 3.26
ABIO ARCA biopharma, Inc. 3.58
ABOS Acumen Pharmaceuticals, Inc. 3.17
ABSI Absci Corporation 4.58
ABUS Arbutus Biopharma Corporation 2.73
ABVC ABVC BioPharma, Inc. 1.42
ABVX Abivax SA American Depositary Shares 15.78
ACAD ACADIA Pharmaceuticals Inc. 16.71
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 1.68
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 0.76
ACHV Achieve Life Sciences, Inc. 4.61
ACIU AC Immune SA 2.35
ACLX Arcellx, Inc. 51.92
ACRV Acrivon Therapeutics, Inc. Common Stock 8.46
ACST Acasti Pharma Inc. 2.9
ETFs With Exposure to GLS
Ticker ETF Name Weight Percentage Price
IWN iShares Russell 2000 Value ETF 0 151.14
HDG ProShares Hedge Replication ETF 0 48.9301
UWM ProShares Ultra Russell2000 0 36.05
IWC iShares Micro-Cap ETF 0 112.63
URTY ProShares UltraPro Russell2000 0 41.61
ISCB iShares Morningstar Small-Cap ETF 0 53.0572
RYLD Global X Russell 2000 Covered Call ETF 0 16.38
SPAK Defiance Next Gen SPAC Derived ETF 0.04 14.63
IEMS.L iShares MSCI EM Small Cap UCITS ETF USD (Dist) 0.01556 88.335
EUNI.DE iShares MSCI EM Small Cap UCITS ETF USD (Dist) 0.01465 82.5
SWSSX Schwab Small-Cap Index Fund-Select Shares 0 32.24
VMMSX Vanguard Emerging Markets Select Stock Fund Investor Shares 0.01 21.53
Unlock